Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
If you have moderate kidney disease, the conversation with your doctor needs to happen before you start
Compounding a drug not in shortage would need to meet one of the FDAs exceptions
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA) (2021)
Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications
US$ 20.83
US$ 29.37
US$ 27.57
US$ 27.55
